Skip to main content

Table 2 Characteristics of the population studied

From: Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies

 Dermatology [n = 38]Gastroenterolgy [n = 42]Haematology [n = 30]Nephrology [n = 45]Rheumatology [n = 49]Combined population [n = 204]
Age [median], years464359585754
Male gender, n [%]21 [47]22 [51]15 [50]20 [44]20 [41]98 [48]
Non-biologic ISDa, n [%]
 Prednisoloneb0 [0]12 [29]22 [73]41 [91]7 14]82 [40]
 Azathioprine0 [0]13 [33]1 [3]3 [7]1 [2]19 [9]
 Methotrexate3 [8]2 [5]2 [7]0 [0]14 [29]21 [10]
 MMFc0 [0]0 [0]1 [3]20 [44]0 [0]21 [10]
 Cyclophosphamide0 [0]0 [0]17 [57]16 [36]1 [2]34 [17]
 Tacrolimus0 [0]0 [0]3 [10]20 [44]0 [0]23 [11]
Biologic ISD, n [%]
 Infliximab1 [3]37 [88]0 [0]0 [0]16 [33]54 [26]
 Adelumimab24 [63]0 [0]1 [3]0 [0]0 [0]15 [12]
 Etanercept0 [0]0 [0]0 [0]0 [0]2 [4]2 [1]
 Secukinumab1 [3]0 [0]0 [0]0 [0]0 [0]1 [0.5]
 Abatacept0 [0]0 [0]0 [0]0 [0]5 [10]5 [2]
 Ustekinumab10 [26]0 [0]0 [0]1 [2]0 [0]11 [5]
 Rituximab1 [3]0 [0]12 [40]10 [22]19 [39]42 [21]
 Tociliuzumab0 [0]0 [0]0 [0]0 [0]8 [16]8 [4]
 Other ISDd, n [%]0 [0]6 [14]16 [53]1 [2]0 [0]23 [11]
Duration of therapy, n [%]
 Up to 4 weeks0 [0]0 [0]0 [0]2 [4]5 [10]7 [3]
 4 weeks to 1 year10 [26]10 [24]14 [47]24 [53]5 [10]63 [31]
 More than 1 year28 [74]32 [74]16 [53]19 [42]39 [80]134 [66]
  1. aISD: immunosuppressant drug; b Or other steroid drug; c Mycophenolate mofitil. d includes both biologic and non-biologic immunosuppressant drugs